Science

Giuseppe Lombardi: Bevacizumab in recurrent glioblastoma – does dose matter?

Giuseppe Lombardi/pugliaeccellente.info

Mar 12, 2025, 09:01

Giuseppe Lombardi: Bevacizumab in recurrent glioblastoma – does dose matter?

Giuseppe Lombardi, Head of the Neuro-Oncology Unit at the Veneto Institute of Oncology, shared a post on LinkedIn about a paper he co-authored with colleagues published in Journal of Neuro-Oncology:

“In this important study, we have shown that in glioblastoma patients, a low dose of bevacizumab (5mg/kg) is as effective as a higher dose (10mg/kg), with less toxicity and less burden on the healthcare system.”

“Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience”

Authors: Giulia Cerretti, Alberto Bosio, Giovanni Librizzi, Giovanna Pintacuda, Mario Caccese, Luca Denaro, Francesco Volpin, Marina Coppola, Sara Lonardi, Giuseppe Lombardi et al.

recurrent glioblastoma

More posts featuring Giuseppe Lombardi.

Alberto Bosio Bevacizumab cancer Francesco Volpin Giovanna Pintacuda Giovanni Librizzi Giulia Cerretti Giuseppe Lombardi glioblastoma Journal of Neuro-Oncology Luca Denaro Marina Coppola Mario Caccese OncoDaily Oncology Sara Lonardi

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage